This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.
McKesson (MCK) to Pay $150 Million to Department of Justice
by Zacks Equity Research
McKesson (MCK) has finalized to resolve U.S. Drug Enforcement Administration and Department of Justice potential federal civil and administrative claims.
McKesson (MCK) Closes Rexall Health Acquisition in Canada
by Zacks Equity Research
McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion
A Whole Lot of Nothing
by Sheraz Mian
Stocks haven't done much lately and the trend will likely continue for some time.
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
by Sheraz Mian
Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).
Where Do We Go From Here?
by Sheraz Mian
The post-Brexit rally has taken many by surprise, but it does beg the question of where we go from here.
Top 6 Research Reports for July 7, 2016
by Sheraz Mian
Today's must-read reports are for Expedia (EXPE), BP (BP) and McKesson (MCK).
Top 6 Research Reports for June 30, 2016
by Sheraz Mian
Today's must-read reports are for Alphabet (GOOGL), Monsanto (MON) and McKesson (MCK).
Top 3 MedTech Stocks Poised to Gain this Earnings Season
by Zacks Equity Research
A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.